Neuronetics (FRA:NRC) Common Stock: €0.6 Mil (As of Mar. 2026)


FRA:NRC Neuronetics Inc FRA:NRC
57 GF Score
Price €1.43
GF Value €1.53
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Neuronetics Common Stock?

Neuronetics FRA:NRC +9.62% 57 Common Stock is €0.6 Mil as of Mar. 2026. GuruFocus rates FRA:NRC with a GF Score™ of 57/100 and a GF Value™ of €1.53 (Fairly Valued). The stock has 4 warning signs investors should review.

Neuronetics's quarterly common stock increased from Sep. 2025 (€0.6 Mil) to Dec. 2025 (€0.6 Mil) and increased from Dec. 2025 (€0.6 Mil) to Mar. 2026 (€0.6 Mil).

Neuronetics's annual common stock increased from Dec. 2023 (€0.3 Mil) to Dec. 2024 (€0.5 Mil) and increased from Dec. 2024 (€0.5 Mil) to Dec. 2025 (€0.6 Mil).

Neuronetics Common Stock Historical Data

* Premium members only.

The historical data trend for Neuronetics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuronetics Common Stock Chart

Neuronetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.23 0.26 0.27 0.53 0.59

Neuronetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.61 0.57 0.58 0.59 0.60
FRA:NRC
57GF Score
Neuronetics Inc FRA:NRC
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuronetics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €0.6 Mil mean?
Neuronetics (FRA:NRC) has a Common Stock of €0.6 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Neuronetics and its competitors.
Is Neuronetics' Common Stock too high?
Neuronetics' current Common Stock is €0.6 Mil. Overall, Neuronetics has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuronetics' Common Stock compare to ZOMDF and OM?
Neuronetics' Common Stock of €0.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Devices & Instruments company?
A good Common Stock depends on the Medical Devices & Instruments industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Neuronetics and its competitors. Neuronetics's current Common Stock is €0.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuronetics stock overvalued right now?
Based on GuruFocus' analysis, Neuronetics (FRA:NRC) is currently considered Fairly Valued. The stock's GF Value™ is €1.53, compared to a current price of €1.43 — trading 6.9% below its estimated fair value. The current Common Stock is €0.6 Mil. Neuronetics' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Neuronetics (FRA:NRC), the current Common Stock is €0.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuronetics (FRA:NRC) Overvalued in 2026?

Based on GuruFocus' analysis, Neuronetics stock appears to be undervalued. The current stock price of €1.43 is trading 6.9% below its estimated GF Value™ of €1.53. GuruFocus considers Neuronetics to be Fairly Valued.

Key valuation signals for FRA:NRC:

  • Common Stock: €0.6 Mil
  • GF Value™: €1.53 vs. price of €1.43 (6.9% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the FRA:NRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuronetics Business Description

Other Exchanges STIM:USA
Address 3222 Phoenixville Pike, Malvern, PA, USA, 19355
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
57GF Score

Get the complete analysis for FRA:NRC

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.43
Price
€1.53
GF Value